SHANGHAI, April 8, 2025 /PRNewswire/ — The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clinical microbiology, infectious diseases, and infection control, ESCMID Global serves as a pivotal platform for scientific exchange. Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", Stock Code: 688373) will present 15 new clinical and preclinical research datasets related to its pipeline products in poster presentations during the conference. The presentations will focus on two core products: Contezolid and MRX-5.
MRX-5: Preclinical and Phase 1 data supporting its potential as a novel treatment for nontuberculous mycobacterial (NTM) pulmonary disease, particularly Mycobacterium abscessus (MAB) infections.
Title
Category
Time
Location
Pharmacokinetic/PharmacodynamicEvaluation of MRX-5 in Murine Models ofMycobacterium abscessus PulmonaryDisease
Oral posterpresentation
April 12,8:30-9:30am
Arena 3
Benzoxaborole Antimycobacterial MRX-5: Preclinical Pharmacokinetics and invitro Drug-Drug Interaction
Top-ratedposter
April 13,12:00-13:30pm
posterarea, Hall D
13-week Repeat-Dose ToxicologyStudies of MRX-5 in Sprague Dawley Ratsand Beagle Dogs
Poster
April 13,12:00-13:30pm
poster
area, Hall D
Safety, tolerability and pharmacokineticsof single and multiple ascending dosesand food-effect of MRX-5 tablets inhealthy adult subjects
Poster
April 13,12:00-13:30pm
posterarea, Hall D
Four studies on MRX-5 presented at the conference
"We are excited to share our latest clinical and scientific advancements at ESCMID Global 2025," Dr. Zhengyu Yuan, Chairman and CEO of MicuRx, stated，"These data highlighted our ongoing commitment to developing innovative therapies to address urgent unmet needs in infectious and chronic pulmonary diseases."
MicuRx invites attendees to visit the poster sessions to engage with the team and learn more about the company’s clinical progress and future development plans.
This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
